Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation Phase 1c Study to Evaluate the Safety and Immunogenicity of an Intranasal Live Attenuated Respiratory Syncytial Virus Vaccine (MV-012-968) in Seronegative Children 6-36 Months

NCT04909021 is registered in ClinicalTrials.gov with Meissa Vaccines, Inc. as lead sponsor.

NCT NCT04909021
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04909021 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation Phase 1c Study to Evaluate the Safety and Immunogenicity of an Intranasal Live Attenuated Respiratory Syncytial Virus Vaccine (MV-012-968) in Seronegative Children 6-36 Months
Lead sponsor
Meissa Vaccines, Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
June 3, 2021
Completion date
October 31, 2023
Enrollment
63 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

respiratory syncytial virus (rsv)